Profactor Pharma Ltd is pleased to announce the appointment of Dr V Paul Gerskowitch to its board.

Dr Gerskowitch joins the board of Profactor Pharma Ltd as an Investor Director with extensive, board level experience in the life sciences industries.  He currently serves as Director and Chairman at Resolomics, a private biotechnology company developing proprietary lipid mediator signatures as novel diagnostics for diagnosis, disease staging and monitoring responses to therapeutic interventions in patients with inflammatory diseases.

Previously, Paul served as an Executive Director at several companies, including Genometrics, the J&J-funded James Black Foundation, the MRC Collaborative Centres at both London and Edinburgh, Lectus Therapeutics, Axordia and was Director of Biomedical Research at Wyeth Research UK.  Later he moved from therapeutic R&D to focus on strategic transactions within the healthcare sector.

“We are excited to welcome Paul Gerskowitch to the Board of Profactor Pharma Ltd,” said Jaymin Amin, CEO of Profactor Pharma.  “Paul’s wealth of experience in advancing molecules into clinical research as well as his track record in corporate strategic transactions will add to the strength of our existing board as we progress our first product towards clinical trials.”

Paul commented, “PFP’s, proprietary, highly cost effective manufacturing process will make rhFVIII available to many more Haemophilia A patients.  Today, according to WHO, the majority of patients either receive no, or inadequate treatment.  I look forward to supporting the team’s efforts to bring this exciting product opportunity to market”.